Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Lilly pens deal with Gateway Labs alumni Amplitude for RNA vaccine platform for infectious disease

Lilly pens deal with Gateway Labs alumni Amplitude for RNA vaccine platform for infectious disease

August 20, 2026Posted inBiotechnology

Eli Lilly has turned to one of its Gateway Labs residents to help the Big Pharma develop trans-amplifying RNA (taRNA) vaccines for infectious diseases.

Post navigation

Previous Post
Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
Next Post
Chai tees up Bristol Myers Squibb AI antibody discovery collab

Recent Posts

  • New Study Charts a Path Toward Democratizing Molecular Innovation
  • Molecular bypasses boost grass lignin and starch synthesis, aiding evolutionary success
  • Brain activity shifts when different generations create together
  • Tandem Quantum-Dot Photodiodes Enable Spectrally Selective 1550-Nanometer LiDAR
  • Isoleucine and Valine Fuel Prostate Cancer Progression by Altering Cholesterol Metabolism

Archives

  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top